Literature DB >> 1347320

Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group.

D R Benjamin1.   

Abstract

The clinical features and management of nine cases of mushroom poisoning due to Amanita pantherina (eight cases) and Amanita muscaria (one case) admitted to a children's hospital are described. Most ingestions were in the toddler age group with males being more frequently involved. Symptoms occurred between 30-180 min with the onset of central nervous system depression, ataxia, waxing and waning obtundation, hallucinations, intermittent hysteria or hyperkinetic behavior. Vomiting was rare. Seizures or myoclonic twitching occurred in 4/9 patients, but was controlled with standard anticonvulsant therapy. No other anticholinergic or cholinergic signs were prominent. Recovery was rapid and complete in all patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347320     DOI: 10.3109/15563659208994442

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  5 in total

1.  GC/MS determination of ibotenic acid and muscimol in the urine of patients intoxicated with Amanita pantherina.

Authors:  Jan Stříbrný; Miloš Sokol; Barbora Merová; Peter Ondra
Journal:  Int J Legal Med       Date:  2011-07-13       Impact factor: 2.686

2.  Prolonged psychosis after Amanita muscaria ingestion.

Authors:  Miran Brvar; Martin Mozina; Matjaz Bunc
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 3.  Mycetism: a review of the recent literature.

Authors:  Kimberlie A Graeme
Journal:  J Med Toxicol       Date:  2014-06

Review 4.  [Mushroom poisonings: syndromic diagnosis and treatment].

Authors:  Peter Kaufmann
Journal:  Wien Med Wochenschr       Date:  2007

Review 5.  Human Poisoning from Poisonous Higher Fungi: Focus on Analytical Toxicology and Case Reports in Forensic Toxicology.

Authors:  Estelle Flament; Jérôme Guitton; Jean-Michel Gaulier; Yvan Gaillard
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.